中文摘要：

目的：总结国内外对恶性腹膜间皮瘤（malignant peritoneal mesothelioma,MPM）综合治疗研究的现状.方法：检索PubMed及CNKI期刊全文数据库系统,以“恶性腹膜间皮瘤、内科治疗、细胞减灭术（cytoreductive surgery,CS）和腹腔热灌注化疗（hyperthermic intraperitoneal chemotherapy,HIPEC）”等关键词检索1983年-2016年相关文献.纳人标准：MPM的CS联合HIPEC治疗;MPM的化疗;MPM的腔内化疗.根据纳人标准符合分析的文献有56篇.结果：多个报道表明联合细胞减灭术及腹腔热灌注化疗治疗MPM能显著提高患者总体生存率（overall survival,OS）及无疾病生存率（progression-free survival,PFS）.联用CS＋HIPEC可提高MPM患者中位总生存期到36-92个月,5年生存率达59%.长期随访中的少数无复发患者提示MPM有潜在治愈的可能.结论：曾经一经诊断即为晚期、致死性高的MPM,现在通过积极的CS＋HIPEC治疗成为一种可治的且有治愈可能的恶性肿瘤.由于MPM发病率低,大样本的多中心随机对照试验非常少,有必要积极倡导针对具体MPM开展前瞻性、大规模、多中心随机临床研究,以获得高水平循证医学证据,确定患者的选择标准、预后因素、最有效的化疗灌注方案及辅助化疗方式.

英文摘要：

Objective： To sum up the status of the combination treatments for malignant peritoneal mesothelioma a-board. Methods：Relevant articles were searched with ＂ malignant peritoneal mesothelioma （ MPM）,medical treat-ment, cytoreductive surgery （CS） and hyperthermic intraperitoneal chemotherapy （ HIPEC） ＂ as key words in PubMed and CNKI database from 1983 to 2016. To tally 56 papers were collected and analyzed according to the in cluding crite -riaas following ： Combined therapies of CS and HIPEC for MPM, chemotherapy of MPM, the intracavitary chemothera-py of MPM. Results ： Multiple research studies demonstrated that combination of CS with HIPEC therapies significantly promoted the overall survival （OS） and progression - free survival （PFS） rates of patients with MPM. The median o-verall survival time would reach up to 36 -92 months, w hi le the five - year survival rate was as high as 5 9 % . Long - term follow - up survey from a few MPM patients without recurrence indicated that MPM has possible potential to be cured thoroughly. Conclusion： MPM,once considered as a malignant and deadly tumo r,n ow becomes a treatable and potentially treatable tumor through CS ＋ HIPEC active treatment. Due to the low incidence of MPM and rared random-ized controlled trials of large samples from multi - centers, it is necessary to carry out prospective, large - scale, multi -center randomized clinical trial against specific MPM to obtain a high level of evidence - based medicine to deter-mine the patients selection criteria,prognostic factors,the most effective chemotherapy infusion plan and adjuvant sys-temic chemotherapy.